Fulcrum Therapeutics (FULC) Liabilities and Shareholders Equity: 2019-2025
Historic Liabilities and Shareholders Equity for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $214.9 million.
- Fulcrum Therapeutics' Liabilities and Shareholders Equity fell 22.99% to $214.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $947.1 million, marking a year-over-year decrease of 10.95%. This contributed to the annual value of $260.7 million for FY2024, which is 1.17% up from last year.
- Per Fulcrum Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $214.9 million for Q3 2025, which was down 6.11% from $228.8 million recorded in Q2 2025.
- Fulcrum Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $321.1 million for Q1 2023, and its period low was $137.9 million during Q2 2021.
- Its 3-year average for Liabilities and Shareholders Equity is $264.6 million, with a median of $260.7 million in 2024.
- Per our database at Business Quant, Fulcrum Therapeutics' Liabilities and Shareholders Equity surged by 81.36% in 2021 and then decreased by 27.57% in 2024.
- Quarterly analysis of 5 years shows Fulcrum Therapeutics' Liabilities and Shareholders Equity stood at $235.0 million in 2021, then fell by 3.54% to $226.7 million in 2022, then grew by 13.68% to $257.7 million in 2023, then grew by 1.17% to $260.7 million in 2024, then declined by 22.99% to $214.9 million in 2025.
- Its Liabilities and Shareholders Equity was $214.9 million in Q3 2025, compared to $228.8 million in Q2 2025 and $242.6 million in Q1 2025.